Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. The brokerage set a “neutral” rating and a $20.00 price target on the biopharmaceutical company’s stock. Goldman Sachs Group’s target price points to a potential upside of 5.60% from the stock’s previous close.
A number of other brokerages have also recently issued reports on HALO. Zacks Investment Research cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, December 25th. BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 5th. Piper Jaffray Companies raised their price objective on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, October 16th. Canaccord Genuity raised their price objective on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. Finally, Barclays cut shares of Halozyme Therapeutics from an “overweight” rating to a “hold” rating and raised their price objective for the company from $16.00 to $19.00 in a research note on Wednesday, November 22nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $19.25.
Shares of Halozyme Therapeutics (HALO) traded up $0.02 during trading on Wednesday, hitting $18.94. 792,705 shares of the company were exchanged, compared to its average volume of 1,340,000. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $2,690.00, a price-to-earnings ratio of -27.85 and a beta of 2.09. Halozyme Therapeutics has a fifty-two week low of $10.79 and a fifty-two week high of $21.13.
Hedge funds have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $131,000. Prudential Financial Inc. increased its stake in shares of Halozyme Therapeutics by 8.7% in the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 940 shares in the last quarter. 361 Capital LLC purchased a new position in shares of Halozyme Therapeutics in the third quarter worth about $207,000. Trexquant Investment LP bought a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $224,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $227,000. Hedge funds and other institutional investors own 84.33% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.